1. Home
  2. KPTI vs MGRM Comparison

KPTI vs MGRM Comparison

Compare KPTI & MGRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • MGRM
  • Stock Information
  • Founded
  • KPTI 2008
  • MGRM 2016
  • Country
  • KPTI United States
  • MGRM United States
  • Employees
  • KPTI 325
  • MGRM N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • MGRM Medical/Dental Instruments
  • Sector
  • KPTI Health Care
  • MGRM Health Care
  • Exchange
  • KPTI Nasdaq
  • MGRM Nasdaq
  • Market Cap
  • KPTI 81.1M
  • MGRM 89.6M
  • IPO Year
  • KPTI 2013
  • MGRM N/A
  • Fundamental
  • Price
  • KPTI $0.66
  • MGRM $2.78
  • Analyst Decision
  • KPTI Strong Buy
  • MGRM Strong Buy
  • Analyst Count
  • KPTI 4
  • MGRM 1
  • Target Price
  • KPTI $5.00
  • MGRM $4.00
  • AVG Volume (30 Days)
  • KPTI 671.2K
  • MGRM 42.8K
  • Earning Date
  • KPTI 02-27-2025
  • MGRM 03-14-2025
  • Dividend Yield
  • KPTI N/A
  • MGRM N/A
  • EPS Growth
  • KPTI N/A
  • MGRM N/A
  • EPS
  • KPTI N/A
  • MGRM N/A
  • Revenue
  • KPTI $148,442,000.00
  • MGRM $364,999.00
  • Revenue This Year
  • KPTI $5.47
  • MGRM N/A
  • Revenue Next Year
  • KPTI $6.33
  • MGRM N/A
  • P/E Ratio
  • KPTI N/A
  • MGRM N/A
  • Revenue Growth
  • KPTI 1.77
  • MGRM N/A
  • 52 Week Low
  • KPTI $0.58
  • MGRM $1.53
  • 52 Week High
  • KPTI $1.70
  • MGRM $4.90
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 46.51
  • MGRM 56.50
  • Support Level
  • KPTI $0.60
  • MGRM $2.62
  • Resistance Level
  • KPTI $0.70
  • MGRM $2.87
  • Average True Range (ATR)
  • KPTI 0.05
  • MGRM 0.14
  • MACD
  • KPTI -0.00
  • MGRM 0.00
  • Stochastic Oscillator
  • KPTI 46.61
  • MGRM 73.09

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About MGRM Monogram Orthopaedics Inc.

Monogram Technologies Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.

Share on Social Networks: